论文部分内容阅读
目的:探讨依达拉奉与盐酸法舒地尔联合治疗高原地区急性脑梗死的疗效和安全性。方法:选取66例高原地区急性脑梗死患者,并随机分成治疗组(依达拉奉+盐酸法舒地尔)34例和对照组(依达拉奉)32例,观察两组治疗前后血清神经元特异性烯醇化酶(NSE)、美国国立卫生研究院卒中量表(NIHSS)和日常生活活动能力量表(BI)评分的变化,并比较出血率及肝、肾功能损害的发生率。结果:两组治疗后血清NSE较治疗前均有明显下降(P<0.05);两组间比较治疗组较对照组NSE水平下降更明显(P<0.05)。两组治疗后NIHSS评分、BI评分比较显示治疗组较对照组的神经功能恢复得更好(P<0.05)。两组出血发生率比较差异无显著性(P>0.05)。所有病例无严重不良反应发生。结论:依达拉奉联合盐酸法舒地尔治疗高原地区急性脑梗死安全、有效。
Objective: To investigate the efficacy and safety of edaravone and fasudil hydrochloride in the treatment of acute cerebral infarction in the high altitude area. Methods: Sixty-six patients with acute cerebral infarction were selected and randomly divided into treatment group (edaravone + fasudil hydrochloride) 34 cases and control group (edaravone) 32 cases. The levels of serum nerve (NSE), NIH Stroke Scale (NIHSS) and daily living activity (BI) scores were compared between the two groups. The rates of hemorrhage and liver and renal dysfunction were compared. Results: The serum NSE in both groups were significantly decreased after treatment (P <0.05). The NSE level in the two groups was significantly lower than that in the control group (P <0.05). NIHSS score and BI score after treatment in both groups showed that the nerve function recovery of the treatment group was better than that of the control group (P <0.05). There was no significant difference in the incidence of bleeding between the two groups (P> 0.05). No serious adverse reactions occurred in all cases. Conclusion: Edaravone combined with fasudil hydrochloride is safe and effective in treating acute cerebral infarction in the high altitude area.